drugset / Trial / NCT00731380

A Phase I Trial of Abraxane, Cisplatin and 5-Fluorouracil Along With Chemoradiotherapy in Advanced Head and Neck Cancer

NCT00731380 ↗

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the highest dose of a ABI-007 that can be given with cisplatin and 5-fluorouracil without causing intolerable side effects in patients with advanced head and neck cancer.

Timeline

Start
2008-07
Primary completion
2016-06
Completion
2016-06

Drugs

EvaluationDrugModalityDoseRoute
Subject ABI-007 Unknown 75 mg/m2 —

Indications